HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system

This item is licensed under:Creative Commons Attribution-NonCommercial 4.0 International

Files in This Item:
rrx083.pdf1.06 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/70251

Title: Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system
Authors: Nishioka, Kentaro Browse this author →KAKEN DB
Prayongrat, Anussara Browse this author
Ono, Kota Browse this author
Onodera, Shunsuke Browse this author
Hashimoto, Takayuki Browse this author →KAKEN DB
Katoh, Norio Browse this author →KAKEN DB
Inoue, Tetsuya Browse this author →KAKEN DB
Kinoshita, Rumiko Browse this author →KAKEN DB
Yasuda, Koichi Browse this author →KAKEN DB
Mori, Takashi Browse this author
Onimaru, Rikiya Browse this author →KAKEN DB
Shirato, Hiroki Browse this author →KAKEN DB
Shimizu, Shinichi Browse this author →KAKEN DB
Keywords: spot-scanning
synchrotron-based
proton beam therapy
safety
toxicity
adverse event
Issue Date: Mar-2018
Publisher: Oxford University Press
Journal Title: Journal of Radiation Research
Volume: 59
Issue: suppl_1
Start Page: i63
End Page: i71
Publisher DOI: 10.1093/jrr/rrx083
Abstract: This is a report of a single-institution prospective study evaluating the safety of a spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy (PBT) system. Data collection was performed for 56 patients with 59 treatment sites who received proton beam therapy at Hokkaido University Hospital between March 2014 and July 2015. Forty-one patients were male and 15 were female. The median age was 66 years. The primary lesion sites were prostate (n = 17), bone/soft tissue (n = 10), liver (n = 7), lung (n = 6), central nervous system (n = 5), colon (n = 2), pancreas (n = 2), kidney (n = 2) and others (n = 5). Chemotherapy was administered in 11 patients. The prescribed total dose was from 20 to 76 GyE (Radiobiological equivalent dose, RBE = 1.1), with the median dose of 65 GyE in 4 to 35 fractions. No PBT-related Common Terminology Criteria for Adverse Events Grade 4 or 5 toxicities were observed; the incidence of early PBT-related Grade 4 adverse events was 0% (95% confidence interval 0 to 6.38%). The most common Grade 3 toxicities were hematologic toxicity (12.5%) unlikely to be related to the PBT. One patient developed a left femoral neck fracture (Grade 3) at 14.5 months after PBT for chondrosarcoma of the left pelvis. The pathological findings showed no other malignancies, suggesting that it was possibly related to the PBT. In conclusion, the spot-scanning dedicated, synchrotron-based PBT system is feasible, but further studies on its long-term safety and efficacy are warranted.
Rights: http://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/70251
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 西岡 健太郎

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University